SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 1 of 76 Clinical Trial Protocol: VISTA- 1 / 18-110-0004  
Protocol  Title:  A Phase 3, Multi -Center, Randomized, Double -Masked, 
Placebo -Controlled Clinical Study to Assess  the Safety 
and Efficacy of SkQ1  Ophthalmic  Solution in the 
Environment and During Challenge in the Controlled 
Adverse Environmental (CAE®) Model for the Treatment 
of Dry Eye  Syndrome 
Protocol  Number:  VISTA -1 / 18-110-0004  
Study Phase:  3 
Product Name:  SkQ1 Ophthalmic Solution  
IND Number:  113433  
Indication:  Dry Eye Syndrome  (DES)  
Investigators:  Multi -Center  
 
Sponsor:  Mitotech , SA 
42, rue de la Vallée  
L-2661 Luxembourg 
 
Contract Research 
Organization: Ora. Inc.  
300 Brickstone Square, 3rd Floor 
Andover, MA 01810 
 
IRB:  Alpha IRB  
1001 Avenida Pico Suite C, #497 San Clemente, CA 92673 
  
 Date  
Original Protocol:  Version 1.0    13 September 2018  
Confidentiality Statement 
This protocol contains confidential, proprietary information of Ora, Inc. and/or Mitotech . 
Further dissemination, distribution or copying of this protocol or its contents is strictly 
prohibited. 
 
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 3 of 76 SYNOPSIS 
Protocol Title:  A Phase 3, Multi -Center, Randomized, Double -
Masked, Placebo -Controlled Clinical Study to 
Assess the Safety and Efficacy of SkQ1  Ophthalmic  
Solution in the Environment and During Challenge 
in the Controlled Adverse Environmental (CAE®) 
Model for the Treatment of Dry Eye  Syndrome  
Protocol Number:  VISTA -1 / 18-110-0004 
Study Drug : 1) 0.155 µg/mL SkQ1 ophthalmic solution  
2) 1.55 µ g/mL SkQ1  ophthalmic solution   
3) Placebo SkQ1 ophthalmic solution (Vehicle of SkQ1 ophthalmic solution) 
Study Phase : 3 
Study Objective:  The objective of this study is to compare the safety and efficacy of SkQ1 ophthalmic solution to placebo for the treatment of  the signs and symptoms of dry 
eye syndrome. 
 
Overall Study Design  
Structure:  Multi -center, double -masked, randomized, placebo -
controlled study 
Duration: An individual subject’s participation is estimated to 
be approximately 9 weeks ( 63 days ) 
Controls: Placebo  SkQ1 ophthalmic solution  (Vehicle of SkQ1 
ophthalmic solution) 
Dosage/Dose Regimen: Subjects  eligible to be randomized will receive one 
of the following treatments to be administered 
bilaterally 1 -2 drops  for 56 days (from Visit 2 
to Visit 5).  
1) 0.155 µg/mL SkQ1 ophthalmic solution  
2) 1.55 µg/mL SkQ1 ophthalmic solution 
3) Placebo SkQ1 ophthalmic solution (Vehicle) 
During a  7-day study run-in period (beginning at the 
end of Vis it 1 for the purpose of subject selection) 
prior to  randomization, all subjects will receive 1-2 
drops of Placebo SkQ1 o phthalmic solution 
(Vehicle) bilaterally    
Summary of Visit Schedule:  5 visits ov er the course of approximately 9 weeks  
• Visit 1 = Day -7 ± 1 day , Environmental 
Screening  
• Visit 2 = Day  1, Baseline , Environmental 
Screening C onfirmation , Randomization and 
Initiation of Double -Masked Treatment  

SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 13 of 76 TABLE OF CONTENTS  
SYNOPSIS  ......................................................................................................................................3  
TABLE OF CONTENTS  ............................................................................................................13  
LIST OF ABBREVIATIONS  .....................................................................................................17  
1 INTRODUCTION...............................................................................................................18  
2 STUDY OBJECTIVES  .......................................................................................................20  
3 CLINICAL HYPOTHESES  ..............................................................................................20  
4 OVERALL STUDY DESIGN  ............................................................................................20  
5 STUDY POPULATION .....................................................................................................21  
5.1 Number of Subjects (approximate)  ........................................................................ 21  
5.2 Study Population Characteristics  .......................................................................... 21  
5.3 Inclusion Criteria  .................................................................................................... 21  
5.4 Exclusion Criteria  .................................................................................................... 22  
5.5 Withdrawal Criteria (if applicable)  ....................................................................... 23  
6 STUDY PARAMETERS  ....................................................................................................24  
6.1 Efficacy Measures  .................................................................................................... 24  
6.1.1  Primary Efficacy Variable s .......................................................................... 24  
6.1.2  Secondary Efficacy Variables  ...................................................................... 24  
6.1.3  Criteria for Effectiveness  ............................................................................. 24  
6.2 Safety Measures  ....................................................................................................... 25  
7 STUDY MATERIALS  ........................................................................................................25  
7.1 Study Drug(s)  ........................................................................................................... 25  
7.1.1  Run- In .......................................................................................................... 25  
7.1.2  Study Drug(s)/ Formulation(s)  ..................................................................... 25  
7.1.3  Study Drug Packaging Configuration .......................................................... 25  
7.1.4  Study D rug Storage and Accountability  ...................................................... 25  
7.1.5  Instructions for Dispensation, Use, and Administration .............................. 26  
7.2 Other Study Supplies  .............................................................................................. 26  
8 STUDY METHODS AND PROCEDURES  .....................................................................27  
8.1 Subject Entry Procedures  ....................................................................................... 27  
8.1.1  Overview  ...................................................................................................... 27  
8.1.2  Informed Consent......................................................................................... 27  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 14 of 76 8.1.3  Washout Intervals  ........................................................................................ 27  
8.1.4  Procedures for Final St udy Entry ................................................................. 27  
8.1.5  Methods for Assignment to Treatment Groups: .......................................... 27  
8.2 Concurrent Therapies  ............................................................................................. 28  
8.2.1  Prohibited Medications/Treatments  ............................................................. 28  
8.2.2  Escape Medications  ..................................................................................... 28  
8.2.3  Special Diet or Activities  ............................................................................. 28  
8.3 Examination Procedures ......................................................................................... 28  
8.3.1  Procedures to be Performed at Each Study Visit with Regard to 
Study Objective(s)  ..................................................................................................... 28  
8.4 Schedule of Visits, Measurements and Dosing  ..................................................... 35  
8.4.1  Scheduled Visits........................................................................................... 35  
8.4.2  Unscheduled Visits ...................................................................................... 35  
8.5 Compliance with Protocol  ....................................................................................... 35  
8.6 Subject Disposition  .................................................................................................. 36  
8.6.1  Completed Subjects ..................................................................................... 36  
8.6.2  Discontinued Subjects .................................................................................. 36  
8.7 Study Termination .................................................................................................. 36  
8.8 Study Duration  ........................................................................................................ 36  
8.9 Monitoring and Quality Assuranc e ....................................................................... 36  
9 ADVERSE EVENTS  ..........................................................................................................37  
9.1 Adverse Event  .......................................................................................................... 37  
9.1.1  Severity  ........................................................................................................ 37  
9.1.2  Relationship to Study Drug .......................................................................... 38  
9.1.3  Expectedness  ................................................................................................ 38  
9.2 Serious Adverse Events  ........................................................................................... 39  
9.3 Procedures for Reporting Adverse Events  ............................................................ 40  
9.3.1  Reporting a Suspected Unexpected Adverse Reaction  ................................ 40  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 15 of 76 9.3.2  Reporting a Serious Adverse Event ............................................................. 40  
9.4 Procedures for Unmasking of Study Drug  ............................................................ 41  
9.5 Type and Duration of the Follow- up of Subjects after Adverse Events  ............. 41  
10 STATISTICAL HYPOTHESES AND METHODS OF ANALYSES ............................41  
10.1  Analysis Populations ............................................................................................... 41  
10.2  Statistical Hypotheses  .............................................................................................. 42  
10.3  Sample Size  .............................................................................................................. 43  
10.4  Statistical Analysis  ................................................................................................... 44  
10.4.1  General Considerations ................................................................................ 44  
10.4.2  Unit of Analysis ........................................................................................... 44  
10.4.3  Missing Data  ................................................................................................ 44  
10.4.4  Multiplicity Adjustments  ............................................................................. 45  
10.4.5  Primary Efficacy Analyses  .......................................................................... 45  
10.4.6  Secondary Efficacy Variables  ...................................................................... 46  
10.4.7  Safety Variables  ........................................................................................... 46  
10.4.8  Interim Analyses  .......................................................................................... 47  
11 COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL 
CONSIDERATIONS, AND ADMINISTRATIVE ISSUES  ............................................47  
11.1  Protection of Human Subjects ................................................................................ 47  
11.1.1  Subject Informed Consent............................................................................ 47  
11.1.2  Institutional Review Board (IRB) Approval ................................................ 47  
11.2  Ethical Conduct of the Study  ................................................................................. 47  
11.3  Subject Confidentiality  ........................................................................................... 48  
11.4  Documentation ......................................................................................................... 48  
11.4.1  Retention of Documentation ........................................................................ 48  
11.5  Labeling, Packaging, Storage, Accountability, and Return or Disposal of 
Study Drug  ............................................................................................................... 49  
11.5.1  Labeling/Packaging ...................................................................................... 49  
11.5.2  Storage of Study Drug  ................................................................................. 49  
11.5.3  Accountability of Study Drug ...................................................................... 49  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 16 of 76 11.5.4  Return or Disposal of Study Drug ............................................................... 49  
11.6  Recording of Data on Source Documents and electronic Case Reports 
Forms (eCRFs) ......................................................................................................... 49  
11.7  Handling of Biological Specimens  .......................................................................... 50  
11.1  Publications  .............................................................................................................. 50  
12 REFERENCES  ....................................................................................................................51  
13 APPENDICES  .....................................................................................................................52  
Appendix 1:  Schedule of Visits and Measurements  .................................................................52  
Appendix 2:  Examination Procedures, Tests, Equipment, and Techniques  .........................54  
Appendix 3: Amendment Summary of Changes .......................................................................74  
Appendix 4:  Sponsor and Ora Approvals  ................................................................................75  
Appendix 5:  Investigator’s Signature .......................................................................................76  
  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 17 of 76 LIST OF ABBREVIATIONS  
AE adverse event  
ANCOVA  Analysis of covariance  
  
 
  
CFR  Code of Federal Regulations  
CI confidence interval  
DES  Dry Eye Syndrome  
DHHS  Department of Health and Human Services  
eCRF  electronic case report form  
EKG  electrocardiograph  
ERC  ethical review committee  
ETDRS  Early Treatment of Diabetic Retinopathy Study  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HIPAA  Health Information Portability and Accountability Act  
ICF informed consent form  
ICH International Conference on Harmonisation  
IND investigational new drug application  
IOP intraocular pressure  
IRB institutional/independent review board  
ITT intent -to-treat 
 IUD intra uterine device  
KCS  keratoconjunctivitis sicca  
kg kilogram  
LASIK  laser in situ  keratomileusis  
logMAR  logarithm of the minimum angle of resolution  
MedDRA  Medical Dictionary for Regulatory Activities  
MGD  meibomian gland dysfunction  
mL milliliter  
mm millimeter  
µg  microgram   
mmHg  millimeters of mercury  
OD right eye  
OS left eye  
OSDI  ocular surface disease index  
OU both eyes  
OTC  over-the-counter  
 
  
  
VA visual acuity  

SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 22 of 76 5.4 Exclusion Criteria 
Subjects must not : 
a. Have participated in the previous SkQ1 ophthalmic solution Phase 2 
treatment study;  
b. Have any clinically significant slit lamp findings at Visit 1 that may include active blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active ocular allergies  that require therapeutic 
treatment , and/or in the opinion of the investigator may interfere with 
study parameters;  
c. Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1;  
d. Have worn contact lenses within 7 days of Visit 1 or a nticipate using 
contact lenses during the study; 
e. Have used any eye drops within 2 hours of Visit 1; 
f. Have previously had laser- assisted in  situ keratomileusis (LASIK) 
surgery within the last 12 months;  
g. Have used Restasis
®,Xiidra® or CEQUATM within  60 days of Visit 1; 
h. Have had any ocular and/or lid surgeries within 6 months of Visit 1 or any planned over the study period; 
i. Be using or anticipate us ing tempor ary punctal plugs during the study 
that have not been stable within 30 days of Visit 1; 
j. Be currently taking any topical ophthalmic prescription (including medications for glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and cannot discontinue these medications for the duration of the trial (excluding medications allowed for the conduct of the study); 
k. Have corrected visual acuity greater than or equal to logMAR +0.7 as 
assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1; 
l. Have an uncontrolled systemic disease;  
m. Be a wom an who is  pregnant, nursing or planning a pregnancy; 
n. Be unwilling to submit a urine pregnancy test at Visit 1  and Visit 5 (or 
early termination visit)  if of childbearing potential. Non-childbearing 
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 36 of 76 8.6 Subject D isposition 
8.6.1 Completed S ubjects  
A completed subject is one who has not been discontinued from the study. 
8.6.2 Discontinued S ubjects  
Subjects may be discontinued prior to their completion of the study due to: 
• adverse events ; 
• protocol violations; 
• administrative reasons ( e.g., inability to continue due to scheduling 
changes);  
• lost to follow up; 
• sponsor termination of study; 
• subject choice (e.g. withdrawal of consent);  and 
• other 
Note: In addition, any subject may be discontinued for any sound medical 
reason at the discretion of the investigator. 
Notification of a subject discontinuation and the reason for discontinuation 
will be made to O ra and/or study sponsor and will be c learly documented 
on the e CRF . 
8.7 Study Termination 
The study may be stopped at any time by the investigator , the sponsor, and/or O ra 
with appropriate notification. 
8.8 Study  Duration 
An individual subjec t’s participation will involve 5 visits over approximately a 9-
week period (63 days) . 
8.9 Monitoring and Quality Assurance 
During the course of the study a monitor, or designee, will make routine site visits to review protocol compliance, assess study drug accountability and storage conditions, subject safety, and ens ure the study is being conducted according to the pertinent 
regulatory requirements.  The review of the subjects’ medical records will be performed in a manner that adequately maintains  subject confidentiality.  Further 
details of the study monitoring will be outlined in a monitoring plan.  
Regulatory authorities of domestic and foreign agencies, Ora, Inc.  quality assurance, 
the sponsor and /or its  designees may carry out on-site inspections and/or audits, 
which may include source data checks.  Therefore direct access to the original source data will be required for inspections and/or audits.  All inspections and audits will be 
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 37 of 76 carried out giving consideration to data protection as well as subject confident iality to 
the extent that local, state, and federal laws  apply. 
9 ADVERSE EVENTS  
9.1 Adverse Event 
An adverse event is defined as any untoward medical occurrence associated with the 
use of a drug in humans, whether or not the event is considered drug- related.  An 
adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease occurring after the subject started  
dosing with the study drug, without any judgment about causality.  Any pre- existing 
medical  condition that worsens after administration of the study drug will also be 
considered a new adverse event.    
If there is a worsening of a medical condition that was present prior to the administration of the study drug, this should also be considered a ne w adverse event 
and reported.  Any medical condition present prior to the administration of the study drug that  remains unchanged or improved should not be recorded as a treatment 
emergent  adverse event at subsequent visits unless it worsens during treatment. 
Study drug includes the investigational drug under evaluation and any comparator drug, placebo , or any other medications required by the protocol given during any 
stage of the study.  
Documentation regarding the adverse event should be made as to the nature, date of onset, end date, severity, relationship to study drug, action(s) taken, seriousness, and outcome of any sign or symptom observed by the physician or reported by the pat ient 
upon indirect questioning.  
9.1.1 Severity  
Severity of an adverse event is defined as a qualitative assessment of the degree of intensity of an adverse event as determined by the investigator 
or reported to him/her by the patient/subject.  The assessment of severity 
is made irrespective of relatio nship to study drug or seriousness of the 
event and should be evaluated according to the following scale: 
• Mild : Event is noticeable to the subject, but is easily tolerated and 
does not interfere with the subject’s daily activities.  
• Moderate : Event is bothersome, possibly requiring additional 
therapy, and may interfere with the subject’s daily activities.  
• Severe: Event is intolerable, necessitates additional therapy or 
alteration of therapy , and interferes with the subject’s daily 
activities.  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 38 of 76 9.1.2 Relationship to Study Drug 
The relationship of each adverse event to the study drug should be 
determined by the investigator using these explanations: 
• Definite : When there are good reason and sufficient documentation 
to demonstrate a direct causal relation ship between investigational 
product and AE; 
• Probable : When there are good reasons and sufficient 
documentation to assume a causal relationship in the sense of plausible, conceivable, likely but not necessarily highly probable. 
• Possible : When there is suff icient information to accept the 
possibility of a causal relationship in the sense of not impossible and not unlikely, although the connection is uncertain or doubtful, for example, due to missing data or insufficient evidence. None : When there is sufficie nt information to accept a lack of a 
causal relationship, in the sense of impossible and improbable. 
• Unclassified : When the causal relationship is not assessable for 
whatever reason due to insufficient evidence, conflicting data or poor documentation. 
Suspected adverse reaction means any adverse event for which there is a reasonable possibility that the study drug caused the adverse event.  “Reasonable possibility” means there is evidence to suggest a causal 
relationship between the stu dy drug and the adver se event.  T ypes of 
evidence that would suggest a causal relationship between the study drug and the adverse event include: a single occurrence of an event that is uncommon and known to be strongly associated with drug exposure (e.g., angioedema, hepatic i njury, Stevens-Johnson Syndrome); one or more 
occurrences of an event that is not commonly associated with drug exposure, but is otherwise uncommon in the population exposed to the drug ( e.g., tendon rupture);  an aggregate analysis of specific events 
observed in a clinical trial (such as known consequences of the underlying disease or condition under investigation or other events that commonly occur in the study population independent of drug therapy) that indicates those events occur more frequently in the drug treatment group than in a concurrent or historical control group. 
9.1.3 Expectedness  
The expectedness of an adverse event should be determined based upon existing safety information about the study drug using these explanations: 
• Unexpected : An adverse event that is not listed in the 
Investigator ’s brochure or is not listed at the specificity or severity 
that has been observed. 
• Expected : An adverse event that is listed in the Investigator’s 
brochure at the specificity and severity that has been observed . 
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 39 of 76 • Not Applicable : Any adverse event that is unrelated to the study 
drug. 
Adverse events that are mentioned in the Investigator’s brochure as 
occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation a re to be considered unexpected.  
The investigator should ini tially c lassif y the expectedness of  an adverse 
event , but the final classification  is subject to the Medical Monitor’s 
determination . 
9.2 Serious Adverse Events 
An adverse event is considered serious if, in the view of either the investigator or sponsor, it results in any of the following outcomes: 
• Death ; 
• A life -threatening adverse event ; 
Note:  An adverse event is considered “li fe-threatening” if, in the view of 
either the investigator or sponsor, its occurrence places the patient or subject at immediate risk of death.  It does not include an adverse event that, had it occurred in a more severe form, might have caused death. 
• Inpatient hospitalization or prolongat ion of existing hospitalization ; 
Note:  The term “inpatient hospitalization” refers to any inpatient admission (even if less than 24 hours).  For chronic or long- term inpatients, inpatient 
admission includes transfer within the hospital to an acute/inte nsive care 
inpatient unit.  Inpatient hospitalization does not include:  emergency room visits; outpatient/same -day/ambulatory procedures; observation/short stay 
units; rehabilitation facilities; hospice facilities; nursing homes; or clinical research/phase 1 units. 
Note:  The term “prolongation of existing hospitalization” refers to any 
extension of an inpatient hospitalization beyond the stay anticipated or required for the reason for the initial admission as determined by the investigator or treating phy sician.  
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions; 
Note:  A serious adverse event specifically related to visual threat would be 
interpreted as any potential impairment or damage to the  subject’s eyes ( e.g., 
hemorrhage, retinal detachment, central corneal ulcer or damage to the optic nerve).  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 40 of 76 • A congenital anomaly/birth defect . 
Important medical events  that may not result in death, ar e life -threatening, or 
require hospitalization may be co nsidered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent one of the outcomes listed in this definition. 
9.3 Procedures for Reporting Adverse Events 
All adverse event s and their outcomes must be reported to O ra, the study sponsor, and 
the IRB as required by the IRB, federal, state, or local regulations and governing health authorities and recorded on the appropriate e CRF .  
9.3.1 Reporting a Suspected U nexpected A dverse Reaction  
All adverse events  that are ‘suspected’ and ‘unexpected’ are to be reported 
to Ora, the study sponsor and the IRB as required by the IRB, federal, 
state, or local  regulations and governing health authorities. 
9.3.2 Reporting a Serious A dverse Event 
To ensure subject safety, all serious adverse events, regardless of relationship to the study drug, must be immediately reported .  All 
information relevant to the serious adverse event must be recorded on the appropriate eCRF .  The investigator is obligated to pursue and obtain 
information requested by Ora and/or the sponsor in addition to that information reported on the eCRF .  All subjects experiencing a serious 
adverse event must be followed up and the outcome reported. 
In the event of a serious adverse event , the investigator must notify Ora 
and the sponsor immediately (within 24 hours) ; obtain and maintain in 
his/her files all pertinent medical records, information , and medical 
judgments from colleagues who assisted in the treatment and follow -up of 
the subject; provide Ora and the study sponsor with a complete case 
history, which includes a statement as to whether the event was or was not 
suspected to be related to the use of the study drug; and inform the IRB of the adverse event within their guidelines for reporting serious adverse events.   
Serious adverse events should be reported within one day to the contacts listed below :  
                                    
                                     
                             
  

SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 41 of 76   
 
  
 
 
 
 
  
 
 
 
 
 
9.4 Procedures for Unmasking of Study Drug  
All subjects, investigators, and study personnel involved with the conduct of the study 
will be masked with regard to treatment assignments. When medically necessary, the investigator may need to determine what treatment  arm has been assigned to a 
subject.  When possible (i.e., in non-emergent situations), O ra and/or the study 
sponsor should be notified before  unmasking study drug . 
If an investigator identifies a medical need for unmasking the treatment assignment of  
a subject, he/she should contact Ora and/or the medical monitor prior to unmasking the identity of the IP, if possible . Ora will ask the site to complete and send them the  
Unmasking Reque st Form. Ora will notify Mitotech  and jointly will determine if the  
unmasking request should be granted. They may consult the medical monitor as needed. The result of the request will be documented on the Unmasking Request Form. If approval is granted to unmask a subject, written permission via the Unmasking Request Form will be provided to the investigator. The investigator will unmask the subject . The investigator will complete the Unmasking Memo form and include it in the subject’s study file and provide a copy for the Trial Master File (TMF). For each unmasked request, the reason, date, signature, and name of the person who unmasked the subject, must be noted in the subject’s study file.  
9.5 Type and Duration of the Follow-up of Subjects after Adverse 
Events 
Adverse events that are ongoing at the end of the study visit will be followed.  Phone 
calls will be placed with any subject who experiences an adverse event until the issue is resolved or the condition is considered ongoing and stable. 
10 STATISTICAL HYPOTHESES AND METHODS OF ANALYSES  
10.1 Analysis Populations 
Intent- to-Treat Population – The intent- to-treat (ITT) population includes all 
randomized subjects. The primary and secondary efficacy analys es will be performed 

SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 47 of 76 10.4.8 Interim Analyses  
There will be no interim analyses.  
11 COMPLIANCE WITH GOOD CLINICAL PRACTICES, 
ETHICAL CONSIDERATIONS , AND ADMINISTRATIVE 
ISSUES  
This study will be conducted in compliance with  the protocol, Good Clinic al Practices 
(GCPs), including the International Conference on Harmonization (ICH) Guidelines, and 
in general, consistent with the Declaration of Helsinki.  In addition, all applicable local, 
state, and federal requirements relevant to the use of study drugs in the countries involved 
will be adhered to. 
11.1 Protection of Human Subjects  
11.1.1 Subject Informed Consent 
Informed consent/assent must take place before any study specific 
procedures are initiated.  Signed and dated written informed consent must be obtained from each subject prior to enrollment into the study.   
All informed consent forms must be approved for use by the sponsor and 
receive approval/favorable op inion from an IRB prior to their use.  If the 
consent form requires revision (e.g., due to a protocol amendment or significant new safety information) , it is the investigator’s responsibility to 
ensure that the amended informed consent is reviewed and approved by Ora prior to submission to the governing IRB and that it is read, signed 
and dated by all subjects subsequently enrolled in the study as well as those currently enrolled in the study. 
11.1.2 Institutional Review Board  (IRB)  Approval 
This study is to be conducted in accordance with Institutional Review Board regulations (U.S. 21 CFR Part 56.103).  The investigator must obtain appropriate IRB approval before initiating the study and re-
approval at least annually. 
Only an IRB approved version of the informed consent form will be used. 
11.2 Ethical Conduct of the Study 
This study will be conducted in accordance with the ethical principles that originated 
with the Declaration of Helsinki.  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 48 of 76 11.3 Subject Confidentiality 
All personal study subject data collected and processed for the purposes of this study 
should be maintained by the investigator and his/her staff with adequate precautions as to ensure that the confidentiality of the data in accordance with local, state, and federal laws  and regulations. 
Monitors, auditors and other authorized representatives of Ora, the sponsor , the IRB  
approving this study, the FDA, the DHHS, other domestic government agencies, and other foreign regulatory agencies will be granted direct access to the study subject’s original medical and stud y records for verification of the data and/or clinical trial 
procedures. Access to this information will be permitted to the aforementioned individuals t o the extent permitted by law.  
A report of the results of this study may be published or sent to the appropriate health authorities in any country in which the study drug may ultimately be marketed, but the subject’s identity will not be  disclosed in these documents. 
11.4 Documentation 
Source documents may include a subject’s medical records, hospital charts, cl inic 
charts, the investigator’s study subject files , as well as t he results of diagnostic tests 
such as X -rays, laboratory tests, and EKGs.  The investigator’s copy of the eCRF  
serves as the investigator’s record of a subject’s study -related data.  
11.4.1 Retentio n of Documentation 
All study -related source documents, correspondence, patient records, 
consent forms, record of the distribution and use of all study drug and copies of case report forms should be maintained on file for at least two years after the last appr oval of a marketing application  in an ICH region 
and until there are no pending or contemplated marketing applications in an ICH region; or until at least two years have elapsed since the formal discontinuation of clinical development of the study drug . These 
documents will be retained for a longer period if required by the applicable regulatory requirements or by an agreement with the sponsor.  It is the responsibility of the sponsor to inform the investigator/institution as to when these documents no longer need to  be retained.  
If the responsible investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping study records, custody must be transferred to a person who will accept the responsibility.  The sponsor must be notified in writing of the name and address of the new custodian. 
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 50 of 76 through the incorrect entry and writing the revi sion next to the corrected data).   An 
individual who has corrected a data entry  should make clear who made the correction 
and when, by adding to the correction his/ her initials as well as the date of the 
correction  
11.7 Handling of Biological Specimens 
Tear samples will be submitted to one or more central laboratories and/or analytical 
laboratories for processing, storage and analysis. All laborator ies meet Good 
Laboratory Practice requirements.  
11.1 Publications 
Authorship and manuscript composition will reflect cooperation among all parties involved in the study.  Authorship will be established before writing the manuscript.  Ora and the study sponsor will have the final decision regarding the manuscript and 
publication. 
  
SkQ1 ophthalmic solution   Sponsor: Mitotech, SA  
Clinical Trial Protocol: VISTA -1 / 18- 110-0004  Final  V 1.0 13Sep 2018 
Confidential  Page 51 of 76 12 REFERENCES  
1. Bakeeva LE, Barskov IV, Egorov MV, et al. Mitochondria- targeted 
plastoquinone derivatives as tools to interrupt execution of the aging program. 2. 
Treat ment of some ROS- and age- related diseases (heart arrhythmia, heart infarctions, 
kidney ischemia, and stroke). Biochemistry Biokhimiia 2008;73:1288-99. 2. Markovets AM, Fursova AZ, Kolosova NG. Therapeutic action of the mitochondria- targeted antioxidant Sk Q1 on retinopathy in OXYS rats linked with 
improvement of VEGF and PEDF gene expression. PloS one 2011;6:e21682. 3. Neroev VV, Archipova MM, Bakeeva LE, et al. Mitochondria- targeted 
plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals. Biochemistry Biokhimiia 2008;73:1317-28. 4. Saprunova VB, Lelekova MA, Kolosova NG, Bakeeva LE. SkQ1 slows development of age- dependent destructive processes in retina and vascular layer of eyes 
of wistar and OXYS rats. Biochemistry Biokhimiia 2012;77:648-58. 5. Saprunova VB, Pilipenko DI, Alexeevsky AV, Fursova A, Kolosova NG, Bakeeva LE. Lipofuscin granule dynamics during development of age- related macular 
degeneration. Biochemistry Biokhimiia 2010;75:130-8. 6. Snytnikova OA, Tsentalovich YP, Stefanova NA, et al. The therapeutic effect of mitochondria- targeted antioxidant SkQ1 and Cistanche deserticola is associated with 
increased levels of tryptophan and kynurenine in the rat lens. Doklady Biochemistry and biophysics 2012;447:300-3. 7. Skulachev VP. What is "phenoptosis" and how to fight it? Biochemistry Biokhimiia 2012;77:689-706.  
 
 
         